Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease

被引：26
|
作者：
Casademont, J
Miró, O
Rodriguez-Santiago, B
Viedma, P
Blesa, R
Cardellach, F
机构：
[1] Univ Barcelona, Fac Med, IDIBAPS, Hosp Clin,Internal Med Dept,Muscle Res Grp, Barcelona 08036, Catalonia, Spain
[2] Univ Barcelona, ICMSN, IDIBAPS, Hosp Clin,Memory Alzheimer Unit, Barcelona 08036, Catalonia, Spain
[3] IRO, Med & Mol Genet Ctr, Barcelona, Spain
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2003年 / 206卷 / 01期
关键词：
mitochondria; electron transport chain; respiratory chain; rivastigmine; neurodegenerative disorders; dementia;
D O I：
10.1016/S0022-510X(02)00319-2
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Electron transport chain (ETC) dysfunction has been claimed to contribute to the expression of neurodegenerative disorders. We have investigated the effects of the treatment with rivastigmine, a commonly used cholinesterase inhibitor, on lymphocyte mitochondria of patients with Alzheimer's disease (AD). Increased enzymatic activities of diverse complexes and oxidative capacity of the ETC were found. Enhanced mitochondrial ETC function may contribute to the beneficial effects of rivastigmine on clinical manifestations of AD. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码：23 / 26
页数：4
相关论文
共 50 条
  • [41] Mitochondrial Function and Parkinson's Disease: From the Perspective of the Electron Transport Chain
    Li, Jeng-Lin
    Lin, Tai-Yi
    Chen, Po-Lin
    Guo, Ting-Ni
    Huang, Shu-Yi
    Chen, Chun-Hong
    Lin, Chin-Hsien
    Chan, Chih-Chiang
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2021, 14
  • [42] Persistence of cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease
    Amuah, Joseph E.
    Hogan, David B.
    Eliasziw, Michael
    Supina, Alison
    Beck, Patricia
    Downey, Winnane
    Maxwell, Colleen J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S223 - S223
  • [43] ADHERENCE TO CHOLINESTERASE INHIBITORS IN PATIENTS WITH ALZHEIMER'S DISEASE
    Blais, Lucie
    Kettani, Fatima-Zohra
    Perreault, Sylvie
    Leroux, Jean-Christophe
    Forget, Amelie
    Kergoat, Marie-Jeanne
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2009, 57 (02) : 366 - 368
  • [44] Switching cholinesterase inhibitors in patients with Alzheimer's disease
    Emre, M
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, : 64 - 72
  • [45] Long-Term Cholinesterase Inhibitor Treatment of Alzheimer’s Disease
    Peter Johannsen
    CNS Drugs, 2004, 18 : 757 - 768
  • [46] Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease
    Lopez, OL
    Becker, JT
    Wisniewski, S
    Saxton, J
    Kaufer, DI
    Dekosky, ST
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 72 (03): : 310 - 314
  • [47] Comment on the preliminary report of the IQWiG "Cholinesterase inhibitor in Alzheimer's disease"
    Gogol, Manfred
    Luettje, Dieter
    Werner, Hansjoerg
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2007, 40 (03): : 192 - 194
  • [48] Current smoking and response to cholinesterase inhibitor therapy in Alzheimer's disease
    Connelly, PJ
    Prentice, NP
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2005, 19 (01) : 11 - 14
  • [49] Risk of antimuscarinic initiation with cholinesterase inhibitor use in Alzheimer's disease
    Chikermane, Soumya G.
    Li, Jieni
    Aparasu, Rajender R.
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2025, 128
  • [50] When do you stop a cholinesterase inhibitor in Alzheimer's disease?
    Brodaty, Henry
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2011, 1 (03) : 191 - 192
12345